Usona Institute
- Company typePrivate
- Founded2014
- HeadquartersMadison, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Usona Institute firmographics
Firmographics- Name
- Usona Institute
- Legal name
- Usona Institute
- Website
- https://usonainstitute.org
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Usona Institute industry classification
Industry- Product category
- Psychedelic Therapeutics Research
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
- akta.pro secondary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where Usona Institute is headquartered
LocationHeadquarters
- HQ city
- Madison
- HQ country
- United States
- HQ region
- North America
Markets served
Usona Institute business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Revenue model
- Nonprofit Research Model: Usona Institute operates as a nonprofit organization developing psychedelic therapies. As a nonprofit pharmaceutical research entity, the revenue model would involve potential licensing of treatments or partnership arrangements post-approval rather than traditional commercial revenue generation.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels2 records
Usona Institute product offering
Product offeringCore offering
Usona Institute is a nonprofit medical research organization conducting clinical research on psilocybin as a potential therapeutic for mental illness, with a primary focus on major depressive disorder. The organization is currently running Phase 3 trials and has received FDA Breakthrough Therapy Designation and a Commissioner's National Priority Voucher to accelerate regulatory review timelines. As a nonprofit pharmaceutical research entity, Usona operates through clinical development and eventual licensing/partnership arrangements rather than direct commercialization.
Product overview
Usona Institute is a nonprofit medical research organization conducting clinical trials on psilocybin-based therapy for major depressive disorder. The organization is in the research and development phase with Phase 3 trials underway, having received Breakthrough Therapy Designation and FDA Commissioner's National Priority Voucher. The company does not have a commercial software product or service offering at this time.
Differentiator
Problem solved
Functional benefit
Products and services
- Psilocybin Therapy for Major Depressive Disorder
Quantifiable outcome
- Accelerated FDA review timeline from 6-10 months to 1-2 months with priority voucher
Companies that use Usona Institute
Customer profileSegments1 record
Ideal customer profiles2 records
Usona Institute technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Usona Institute partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- FDA (U.S. Food and Drug Administration)coreThe FDA awarded Usona Institute a Commissioner's National Priority Voucher following President Trump's executive order directing the agency to accelerate research and approval of psychedelic therapies for mental health. This voucher provides priority communication with the FDA and accelerated 1- to 2-month review timelines (compared to standard 6-10 months) for approval applications.
Scale indicators3 records
Recent moves3 records
Expansion highlights4 records
Usona Institute competitors and assessment
Company assessmentDirect peers
- Compass Pathways: Compass Pathways is the most direct peer to Usona: a clinical-stage psychedelic therapy company also in Phase 3 trials of psilocybin for treatment-resistant depression, also holder of an FDA Commissioner's National Priority Voucher, and the other most-cited scientific source on psilocybin for depression alongside Usona.
- Transcend Therapeutics: Transcend Therapeutics was the third co-recipient of the FDA Commissioner's National Priority Voucher alongside Usona, also focused on psychedelic-derived therapies for mental illness, making it a closely comparable regulatory-stage peer.
- MindMed: MindMed is a clinical-stage psychedelic medicine company developing psychedelic-inspired therapies for mental health and addiction, including MDD-adjacent indications, with publicly traded capital access — a direct competitor in the same therapeutic and regulatory category.
- Atai Life Sciences: Atai Life Sciences is a clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health disorders including depression, with multiple psychedelic programs and a publicly listed platform comparable in scope to Usona's MDD focus.
- GH Research: GH Research is a clinical-stage company developing mebufotenin and other 5-HT2A agonist psychedelic therapies for treatment-resistant depression — directly comparable to Usona's MDD psychedelic approach and patient population.
- Cybin: Cybin is a clinical-stage psychedelic therapeutics company developing deuterated psilocybin analogs for depression and other psychiatric indications, representing a direct pipeline-level peer to Usona's psilocybin MDD program.
- MAPS / MAPS PBC: MAPS (Multidisciplinary Association for Psychedelic Studies) is a nonprofit psychedelic research organization pursuing MDMA-assisted therapy through FDA approval — directly comparable to Usona as a mission-driven nonprofit advancing psychedelic therapy through the regulatory pathway.
Emerging players
- Beckley Psytech: Beckley Psytech is a private clinical-stage psychedelic medicine company developing psilocybin and 5-MeO-DMT-based therapies for depression and other CNS indications, overlapping with Usona's therapeutic area at an earlier stage of development.
- Filament Health: Filament Health is a botanical psychedelic drug development company focused on naturally-derived psilocybin, comparable to Usona as a potential manufacturing/development peer for psilocybin-based therapies.
Regional players
- Johns Hopkins Center for Psychedelic and Consciousness Research: Johns Hopkins Center for Psychedelic and Consciousness Research is a leading academic research center conducting clinical trials of psilocybin for depression and other indications — a nonprofit scientific peer whose research underpins much of the field, including Usona's evidence base.
Market position
Strengths5 records
Weaknesses3 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Usona Institute social profiles
Digital presenceUsona Institute financial estimates
Financial estimateRevenue estimate
Valuation estimate
Usona Institute leadership team
Management profileNumber of profiles
Usona Institute funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Usona Institute M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Usona Institute
What does Usona Institute do?
Usona Institute is a nonprofit medical research organization conducting clinical research on psilocybin as a potential therapeutic for mental illness, with a primary focus on major depressive disorder. The organization is currently running Phase 3 trials and has received FDA Breakthrough Therapy Designation and a Commissioner's National Priority Voucher to accelerate regulatory review timelines. As a nonprofit pharmaceutical research entity, Usona operates through clinical development and eventual licensing/partnership arrangements rather than direct commercialization.
Is Usona Institute a public or private company?
Usona Institute is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Usona Institute founded?
Usona Institute was founded in 2014. It employs 11 to 50 people.
Where is Usona Institute based?
Usona Institute is headquartered in Madison, United States, in the North America region.
How does Usona Institute make money?
One revenue line is on record: nonprofit Research Model.
Who are Usona Institute's main competitors?
Direct peers on record are Compass Pathways, Transcend Therapeutics, MindMed, Atai Life Sciences, GH Research, Cybin and MAPS / MAPS PBC. Emerging players are Beckley Psytech and Filament Health. Johns Hopkins Center for Psychedelic and Consciousness Research is listed as a regional player.
Does Usona Institute have an API?
No public API is recorded for Usona Institute.
What industry is Usona Institute in?
Usona Institute's product category is Psychedelic Therapeutics Research. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 541714 and its SIC code is 8731.